The global drug market for migraine treatment is massive, and is expected to be worth around SEK 83.7 billion a year within the next six years. Our treatment method, Kinetic Oscillation Stimulation, K.O.S, is currently the subject of a large international clinical study which will be completed in the fourth quarter of 2020. In 2019, an interim analysis confirmed the design of the study, indicating that it is likely to achieve its desired result. Our shares are listed on the Nordic Growth Market – SME.
During treatment, the patient may experience some discomfort in the nose, but aside from that, K.O.S. has no other negative side effects.
K.O.S can in many cases replace the medication used to treat migraine today. This means that many migraine patients can avoid pills and/or injections.
K.O.S treatment is cost effective, resulting also in less sick leave and reduced productivity losses.
The global drug market to treat migraine is growing and is expected to be worth SEK 83.7 billion by 2026.
By building an extensive patent portfolio, carrying out clinical trials and demonstrating commercial success stories we attract prospective buyers.
A ground-breaking international migraine study expected to be completed in the first half of 2021 has received clear positive indications from an interim analysis.
K.O.S was initially used to treat rhinitis, but doctors discovered it can also be used to treat migraine.
For questions about Chordate's share price or other investment-related topics, please see if the answer is here.
For questions about the medical effects of the K.O.S treatment, please see if the answer is here.
To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.
The information is handled according to our privacy policy.
This website uses cookies to give you the best and most relevant user experience. Using this website means you consent to the use of cookies. Find out more about cookies on our website.